151 related articles for article (PubMed ID: 21372544)
1. Dose conversion in opioid rotation from continuous intravenous infusion of morphine hydrochloride injection to fentanyl patch in the management of cancer pain.
Kawano C; Hirayama T; Kuroyama M
Yakugaku Zasshi; 2011 Mar; 131(3):463-7. PubMed ID: 21372544
[TBL] [Abstract][Full Text] [Related]
2. [Optimal conversion ratio of oral morphine to transdermal fentanyl patches to the cancer pain].
Ogawa J; Nakamura K; Iizuka K; Sekizuka M; Yamamoto K; Horiuchi R
Yakugaku Zasshi; 2009 Mar; 129(3):335-40. PubMed ID: 19252390
[TBL] [Abstract][Full Text] [Related]
3. Opioid rotation from transdermal fentanyl to continuous subcutaneous hydromorphone in a cachectic patient: A case report and review of the literature.
Jackson LD; Wortzman R; Chua D; Selby D
J Oncol Pharm Pract; 2021 Jan; 27(1):238-243. PubMed ID: 32501183
[TBL] [Abstract][Full Text] [Related]
4. [A study of transdermal fentanyl in cancer pain at Aichi-Cancer Center].
Kato K; Mizaki T; Yamazaki S; Nitta M; Hasegawa M; Kamiya Y; Hosoda R
Yakugaku Zasshi; 2004 May; 124(5):287-91. PubMed ID: 15118241
[TBL] [Abstract][Full Text] [Related]
5. [2 cases of successful symptom management at home by using opioid rotation from a fentanyl preparation to a continuous subcutaneous injection of morphine hydrochloride, at a dose less than the equivalent dose based on the conversion table].
Sato M; Miyamori T; Koyanagi J; Murase J; Saka S; Ishii N; Nishi T; Yamagishi T
Gan To Kagaku Ryoho; 2012 Dec; 39 Suppl 1():58-60. PubMed ID: 23268901
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
7. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
9. The opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients.
Reddy A; Tayjasanant S; Haider A; Heung Y; Wu J; Liu D; Yennurajalingam S; Reddy S; de la Cruz M; Rodriguez EM; Waletich J; Vidal M; Arthur J; Holmes C; Tallie K; Wong A; Dev R; Williams J; Bruera E
Cancer; 2016 Jan; 122(1):149-56. PubMed ID: 26451687
[TBL] [Abstract][Full Text] [Related]
10. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.
Donner B; Zenz M; Tryba M; Strumpf M
Pain; 1996 Mar; 64(3):527-534. PubMed ID: 8783318
[TBL] [Abstract][Full Text] [Related]
11. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial.
Morita T; Takigawa C; Onishi H; Tajima T; Tani K; Matsubara T; Miyoshi I; Ikenaga M; Akechi T; Uchitomi Y;
J Pain Symptom Manage; 2005 Jul; 30(1):96-103. PubMed ID: 16043013
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
[TBL] [Abstract][Full Text] [Related]
13. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl.
Kornick CA; Santiago-Palma J; Khojainova N; Primavera LH; Payne R; Manfredi PL
Cancer; 2001 Dec; 92(12):3056-61. PubMed ID: 11753984
[TBL] [Abstract][Full Text] [Related]
14. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
15. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
16. Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit.
Botterman J; Criel N
Palliat Med; 2011 Mar; 25(2):111-6. PubMed ID: 20937611
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of analgesic effect and safety of fentanyl transdermal patch for cancer pain as the first line.
Hoya Y; Okamoto T; Yanaga K
Support Care Cancer; 2010 Jun; 18(6):761-4. PubMed ID: 20354734
[TBL] [Abstract][Full Text] [Related]
18. A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain.
Kornick CA; Santiago-Palma J; Schulman G; O'Brien PC; Weigand S; Payne R; Manfredi PL
Cancer; 2003 Jun; 97(12):3121-4. PubMed ID: 12784350
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparations].
Akiyama Y; Iseki M; Izawa R; Ishii K; Miyazaki T; Yamaguchi S; Tani Y
Masui; 2007 Mar; 56(3):317-23. PubMed ID: 17366919
[TBL] [Abstract][Full Text] [Related]
20. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial.
Viscusi ER; Reynolds L; Chung F; Atkinson LE; Khanna S
JAMA; 2004 Mar; 291(11):1333-41. PubMed ID: 15026400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
